Instil Bio (TIL) Cash from Operations (2020 - 2026)

Instil Bio has reported Cash from Operations for 7 years, with the latest figure at -$4.6 million in Q2 2026.

• On a quarterly basis, Cash from Operations rose 68.62% year-over-year to -$4.6 million in Q2 2026; TTM through Jun 2026 was -$23.6 million, a 52.47% increase from a year earlier, with the FY2025 full-year figure at -$36.6 million, up 34.25% from the prior year.
• Cash from Operations was -$4.6 million for Q2 2026 at Instil Bio, down from -$1.3 million in the prior quarter.
• The five-year high for Cash from Operations was -$1.3 million in Q1 2026, with the low at -$55.1 million in Q1 2022.
• Average Cash from Operations over 5 years is -$20.0 million, with a median of -$14.4 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations plunged 210.51% in 2022, then surged 70.85% in 2025.
• Over 5 years, Cash from Operations stood at -$37.0 million in 2022, then soared by 63.81% to -$13.4 million in 2023, then rose by 21.09% to -$10.6 million in 2024, then jumped by 32.99% to -$7.1 million in 2025, then surged by 34.4% to -$4.6 million in 2026.
• The last three Cash from Operations figures came in at -$4.6 million (Q2 2026), -$1.3 million (Q1 2026), and -$7.1 million (Q4 2025), per Business Quant data.